medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2019-1-64-71medsovet-2900Research ArticleРЕВМАТОЛОГИЯRHEUMATOLOGYТофацитиниб: эффективность и безопасность при длительном примененииTofacitinib: efficiency and safety in long-term useЧичасоваН. В.ChichasovaN. V.

д.м.н., профессор кафедры ревматологии Института последипломного образования Федерального государственного автономного образовательного учреждения высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский университет); Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт ревматологии имени В.А. Насоновой»

Dr. of Sci. (Med), Professor of the Department of Rheumatology at the Institute of Postgraduate Education of the Federal State Autonomous Educational Institution of Higher Education «I.M. Sechenov First Moscow State Medical University named after I.M. Sechenov» of the Ministry of Health of the Russian Federation (Sechenov University); Federal State Budgetary Scientific Institution «Research Institute of Rheumatology named after V.A. Nasonova»

kafedrarheum@yandex.ruФедеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский университет)РоссияFederal State Autonomous Educational Institution of Higher Education «First Moscow State Medical University named after I.M. Sechenov» of the Ministry of Health of the Russian Federation (Sechenov University); Federal State Budgetary Scientific Institution «Research Institute of Rheumatology named after V.A. Nasonova»Russian Federation201905032019016471Copyright © Чичасова Н.В., 20192019Чичасова Н.В.Chichasova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2900

В статье приведены данные международных и отечественных контролируемых исследований, в которых оценена эффективность тофацитиниба в сроки 6–24 месяца в отношении клинико-лабораторных проявлений активности РА, прогрессирования деструктивного артрита и функциональной способности больных ревматоидным артритом. Также приведены данные эффективности и безопасности тофацитиниба в длительные сроки – до 96 месяцев. В соответствии с результатами краткосрочных и долгосрочных исследований тофацитиниб является высокоэффективным препаратов для лечения больных активным РА, не ответивших на стандартную терапию сБПВП и ГИБП. Тофацитиниб высокоэффективен и в режиме монотерапии. Переносимость препарата сопоставима с другими вариантами лечения РА.

The article presents the data of international and domestic controlled studies, in which the effectiveness of topacitinib in the period of 6-24 months is evaluated in respect of clinical and laboratory manifestations of RA activity, progression of destructive arthritis and functional ability of rheumatoid arthritis patients. Also the data of efficiency and safety of tofacitinib in long terms - up to 96 months - are given. According to the results of short- and long-term studies, tofacitinib is a highly effective drug for the treatment of patients with active RA who have not responded to standard therapy with UCVD and GIBP. Tofacitinib is also highly effective in monotherapy. Tolerability of the drug is comparable with other variants of RA treatment.

ревматоидный артриттофацитинибэффективностьбезопасностьrheumatoid arthritistofacitinibefficacysafetyReferencesSmolen J.S., Landewe R., Bijlsma J., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76: 960-977.Smolen J.S., Landewe R., Bijlsma J., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76: 960-977.Smolen J.S., Aletaha D., Bijlsma J.W., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010; 69: 631-637.Smolen J.S., Aletaha D., Bijlsma J.W., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010; 69: 631-637.Winthrop K.L., Strand V., van der Heijde D.M., et al. The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016. Clin Exp Rheumatol. 2016; 34(4 Suppl 98): 69-76.Winthrop K.L., Strand V., van der Heijde D.M., et al. The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016. Clin Exp Rheumatol. 2016; 34(4 Suppl 98): 69-76.Meyer D.M., Jesson M.I., Li X., et al. Antiinflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm. 2010; 7: 41.Meyer D.M., Jesson M.I., Li X., et al. Antiinflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm. 2010; 7: 41.Karaman M.W., Herrgard S., Treiber D.K., et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008; 26: 127-132.Karaman M.W., Herrgard S., Treiber D.K., et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008; 26: 127-132.Hodle J.A., Kawabata T.T., Krishnaswami S., et al. The mechanism of action of tofacitinib – an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumat. 2016; 34: 318-328.Hodle J.A., Kawabata T.T., Krishnaswami S., et al. The mechanism of action of tofacitinib – an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumat. 2016; 34: 318-328.Насонов Е.Л. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017; 55(4):409-19.Nasonov E.L. Pharmacotherapy of rheumatoid arthritis: new strategy, new targets. [Nauchno-prakticheskaya revmatologiya] Scientific and practical rheumatology. 2017; 55(4):409-19. (In Russ).Maeshima K., Yamoaka K., Kubo S., et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ N cells. Arthr Rheum. 2012; 64: 1790-1798.Maeshima K., Yamoaka K., Kubo S., et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ N cells. Arthr Rheum. 2012; 64: 1790-1798.Pfizer Ltd. Xeljanz (tofacitinib): summary of product characteristics. 2017. http://www.ema. europa.eu/does/en_GB/document_library/ EPAR_-_Product_Information/human/004214/ WC500224911.pdf. Accessed 31 Oct 2017.Pfizer Ltd. Xeljanz (tofacitinib): summary of product characteristics. 2017. http://www.ema. europa.eu/does/en_GB/document_library/ EPAR_-_Product_Information/human/004214/ WC500224911.pdf. Accessed 31 Oct 2017.Lee E.B., Fleischmann R., Hall S., et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014; 370: 2377-2386.Lee E.B., Fleischmann R., Hall S., et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014; 370: 2377-2386.Fleischmann R., Kremer J., Cush J., et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012; 367: 495-507.Fleischmann R., Kremer J., Cush J., et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012; 367: 495-507.Fleischmann R., Mysler E., Hall S., et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, doubleblind, head-to-head, randomized controlled trial. Lancet. 2017; 390: 457-468.Fleischmann R., Mysler E., Hall S., et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, doubleblind, head-to-head, randomized controlled trial. Lancet. 2017; 390: 457-468.Van der Heijde D., Tanaka Y., Fleischmann R., et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthr Rheum. 2013; 65:559-570.Van der Heijde D., Tanaka Y., Fleischmann R., et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthr Rheum. 2013; 65:559-570.Van Vollenhoven R.F., Fleischmann R., Cohen S., et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012; 367: 508-519.Van Vollenhoven R.F., Fleischmann R., Cohen S., et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012; 367: 508-519.Kremer J., Li Z.G., Hall S., et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013; 159: 253-261.Kremer J., Li Z.G., Hall S., et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013; 159: 253-261.Burmester G.R., Blanco R., Charles-Schoeman C., et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomized phase 3 trial. Lancet. 2013; 381: 451-460.Burmester G.R., Blanco R., Charles-Schoeman C., et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomized phase 3 trial. Lancet. 2013; 381: 451-460.Fleischmann R., Mease P.J., Schwartzman S., et al. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group. Clin Rheum. 2017; 36: 15-24.Fleischmann R., Mease P.J., Schwartzman S., et al. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group. Clin Rheum. 2017; 36: 15-24.Strand V., van Vollenhoven R.F., Lee E.B., et al. Tofacitinib or adalimumab versus placebo: patient reported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatology (Oxford). 2016; 55: 1031-1041.Strand V., van Vollenhoven R.F., Lee E.B., et al. Tofacitinib or adalimumab versus placebo: patient reported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatology (Oxford). 2016; 55: 1031-1041.Landewe R.B., Connell C.A., Bradley J.D., et al. Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials. Arthritis Res Ther. 2016; 18: 212.Landewe R.B., Connell C.A., Bradley J.D., et al. Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials. Arthritis Res Ther. 2016; 18: 212.Российские клинические рекомендации. Ревматология. Под ред. академика РАН Насонова Е.Л. М.: «ГЭОТАР-Медиа». 2017, 456 с.Russian clinical recommendations. Rheumatology. Edited by Academician Nasonov E.L. M.: «GEOTAR-Media». 2017, 456 с. (In Russ).Лучихина Е.Л., Каратеев Д.Е., Демидова Н.В. и др. Эффективность и безопасность терапии тофацитинибом у больных активным ревматоидным артритом с резистентностью к стандартной терапии: предварительные результаты открытого клинического исследования. Совр ревматология. 2016; 10 (2): 17-23.Luchikhina E.L., Karateev D.E., Demidova N.V., et al. Efficacy and safety of tofacitinib therapy in patients with active rheumatoid arthritis with resistance to standard therapy: preliminary results of an open clinical study. [Sovr revmatologiya] Modern rheumatology. 2016; 10 (2): 17-23. (In Russ).Fleischmann R., Wollenhaupt J., Takiya L., et al. Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. RMD Open. 2017; 3:e000491. doi10.1136/rmdopen-2017-000491.Fleischmann R., Wollenhaupt J., Takiya L., et al. Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. RMD Open. 2017; 3:e000491. doi10.1136/rmdopen-2017-000491.Fleischmann R., van Vollenhoven R.F., Vencovsky J., et al. Long-term maintenance of certolizumab pegol safety and efficacy, in combination with methotrexate and as monotherapy, in rheumatoid arthritis patients. Rheumatol Ther. 2017; 4: 57-69.Fleischmann R., van Vollenhoven R.F., Vencovsky J., et al. Long-term maintenance of certolizumab pegol safety and efficacy, in combination with methotrexate and as monotherapy, in rheumatoid arthritis patients. Rheumatol Ther. 2017; 4: 57-69.Klareskog L., Gaubitz M., Rodriguez-Valverde V., et al. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2011; 29: 238-247.Klareskog L., Gaubitz M., Rodriguez-Valverde V., et al. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2011; 29: 238-247.Furst D.E., Kavanaugh А., Florentius S., et al. Final 10-year effectiveness and safety results from study DEO20: adalimumab treatment in patients with rheumatoid arthritis and inadequate response to standard therapy. Rheumatology. 2015; 54: 2188-2197.Furst D.E., Kavanaugh А., Florentius S., et al. Final 10-year effectiveness and safety results from study DEO20: adalimumab treatment in patients with rheumatoid arthritis and inadequate response to standard therapy. Rheumatology. 2015; 54: 2188-2197.Curtis J.R., Schulze-Koops H., Takiya L., et al. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. Clin Exp Rheumatol. 2017; 35: 390-400.Curtis J.R., Schulze-Koops H., Takiya L., et al. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. Clin Exp Rheumatol. 2017; 35: 390-400.Watanabe T., Hattori T., Ogawa S.Y., Jodo S. Successful treatment with tofacitinib for renal disorder due to amyloid A amyloidosis and immunoglobulin A nephropathy in patient with rheumatoid arthritis. Clin Exp Rheumatol. 2018; 36:683-684.Watanabe T., Hattori T., Ogawa S.Y., Jodo S. Successful treatment with tofacitinib for renal disorder due to amyloid A amyloidosis and immunoglobulin A nephropathy in patient with rheumatoid arthritis. Clin Exp Rheumatol. 2018; 36:683-684.Hagihara R., Nishikawa T., Isobe T., et al. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophis Res Commun. 2004; 314: 363-369.Hagihara R., Nishikawa T., Isobe T., et al. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophis Res Commun. 2004; 314: 363-369.Migita K., Koga T., Komori A., et al. Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium. J Rheumatol. 2011; 38: 2309-2317.Migita K., Koga T., Komori A., et al. Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium. J Rheumatol. 2011; 38: 2309-2317.Migita K., Izumi Y., Jiuchi Y., et al. Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis. Clin Exp Immunol. 2014; 175: 208-214.Migita K., Izumi Y., Jiuchi Y., et al. Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis. Clin Exp Immunol. 2014; 175: 208-214.Hodge J.A., Kawabata T.T., Krishnaswami S., et al. The mechanism of action of tofacitinib – an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016; 34: 318-328.Hodge J.A., Kawabata T.T., Krishnaswami S., et al. The mechanism of action of tofacitinib – an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016; 34: 318-328.Schwartz D.M., Kanno Y., Villarini A., et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017; 16: 843-862.Schwartz D.M., Kanno Y., Villarini A., et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017; 16: 843-862.Singh J.A., Hossain A., Tanjong Ghogomu E., et al. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis (Review). Cochrane Database of Systematic Reviews. 2017, Issue 3. Art. No.: CD012591. doi: 10.1002/14651858.CD012591.Singh J.A., Hossain A., Tanjong Ghogomu E., et al. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis (Review). Cochrane Database of Systematic Reviews. 2017, Issue 3. Art. No.: CD012591. doi: 10.1002/14651858.CD012591.

The authors declare that there are no conflicts of interest present.